• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors

tetano

Editor, Senior Moderator
Bioorg Med Chem Lett. 2018 Oct 26. pii: S0960-894X(18)30843-6. doi: 10.1016/j.bmcl.2018.10.040. [Epub ahead of print]
[h=1]Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors.[/h] Cheng LP[SUP]1[/SUP], Wang TC[SUP]2[/SUP], Yu R[SUP]2[/SUP], Li M[SUP]2[/SUP], Huang JW[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Neuraminidase (NA) is an important antiviral drug target. Zanamivir is one of the most potent NA inhibitors. In this paper, a series of zanamivir derivatives as potential NA inhibitors were studied by combination of molecular modeling techniques including 3D-QSAR, molecular docking, and molecular dynamics (MD) simulation. The results show that the best CoMFA (comparative molecular field analysis) model has q[SUP]2[/SUP] = 0.728 and r[SUP]2[/SUP] = 0.988, and the best CoMSIA (comparative molecular similarity indices analysis) model has q[SUP]2[/SUP] = 0.750 and r[SUP]2[/SUP] = 0.981, respectively. The built 3D-QSAR models show significant statistical quality and excellent predictive ability. Seven new NA inhibitors were designed and predicted. 20 ns of MD simulations were carried out and their binding free energies were calculated. Two designed compounds were selected to be synthesized and biologically evaluated by NA inhibition and virus inhibition assays. One compound (IC[SUB]50[/SUB] = 0.670 ?M, SI > 149) exhibits excellent antiviral activity against A/WSN/33 H1N1, which is superior to the reference drug zanamivir (IC[SUB]50[/SUB] = 0.873 ?M, SI > 115). The theoretical and experimental results may provide reference for development of new anti-influenza drugs.


[h=4]KEYWORDS:[/h] 3D-QSAR; Antiviral activity; H1N1; Neuraminidase inhibitors; Zanamivir derivatives

PMID: 30389293 DOI: 10.1016/j.bmcl.2018.10.040
 
Back
Top Bottom